Table 4.
Potential risk factors for PFS across the entire cohort.
| Risk factors | Univariable | P value | Multivariable | P value |
|---|---|---|---|---|
| HR (95% CI) | Adjusted HR (95% CI) | |||
| Sex (Male, Female) | 0.510 (0.154–1.693) | 0.272 | ||
| Age (< 60 y, ≥ 60 y) | 1.260 (0.587–2.702) | 0.553 | ||
| ECOG performance status (0-1, 2) | 2.428 (1.172–5.032) | 0.017# | 2.719 (1.293–5.721) | 0.008* |
| HBs–Ag (+, −) | 0.410 (0.141–1.189) | 0.101 | ||
| AFP (<400 ng/mL, ≥400 ng/mL) | 1.439 (0.707–2.931) | 0.316 | ||
| Child–Pugh class (A, B) | 0.973 (0.465–2.034) | 0.941 | ||
| Largest tumor size (< 5 cm, ≥ 5cm) | 1.117 (0.453–2.752) | 0.810 | ||
| BCLC stage (A, B, C) | 1.156 (0.585–2.284) | 0.676 | ||
| Liver tumor number (<3, ≥3) | 0.634 (0.306–1.312) | 0.219 | ||
| Macro vascular invasion (+, −) | 0.671 (0.331–1.359) | 0.268 | ||
| Extrahepatic metastasis (+, −) | 0.837 (0.412–1.701) | 0.623 | ||
| cTACE treatment (+, −) | 2.195 (1.051–4.587) | 0.037# | 2.466 (1.169–5.243) | 0.019* |
#p < 0.1, *p < 0.05.